Abstract. The present study assessed the beneficial skeletal muscle-preserving effects of extracellular polysaccharides from *Aureobasidium pullulans* SM-2001 (Polycan) (EAP) on dexamethasone (DEXA)-induced catabolic muscle atrophy in mice. To investigate whether EAP prevented catabolic DEXA-induced muscle atrophy, and to examine its mechanisms of action, EAP (100, 200 and 400 mg/kg) was administered orally, once a day for 24 days. EAP treatment was initiated 2 weeks prior to DEXA treatment (1 mg/kg, once a day for 10 days) in mice. Body weight alterations, serum biochemistry, calf thickness, calf muscle strength, gastrocnemius muscle thickness and weight, gastrocnemius muscle antioxidant defense parameters, gastrocnemius muscle mRNA expression, histology and histomorphometry were subsequently assessed. After 24 days, DEXA control mice exhibited muscle atrophy according to all criteria indices. However, these muscle atrophy symptoms were significantly inhibited by oral treatment with all three doses of EAP. Regarding possible mechanisms of action, EAP exhibited favorable ameliorating effects on DEXA-induced catabolic muscle atrophy via antioxidant and anti-inflammatory effects; these effects were mediated by modulation of the expression of genes involved in muscle protein synthesis (AKT serine/threonine kinase 1, phosphatidylinositol 3-kinase, adenosine A1 receptor and transient receptor potential cation channel subfamily V member 4) and degradation (atrogin-1, muscle RING-finger protein-1, myostatin and sirtuin 1). Therefore, these results indicated that EAP may be helpful in improving muscle atrophies of various etiologies. EAP at 400 mg/kg exhibited favorable muscle protective effects against DEXA-induced catabolic muscle atrophy, comparable with the effects of oxymetholone (50 mg/kg), which has been used to treat various muscle disorders.

Introduction

Aging is associated with a progressive reduction in muscle mass and strength (1,2), which is known as sarcopenia. Sarcopenia is recognized as an important risk factor associated with disability and mortality (3). Daily life is largely affected by the loss of skeletal muscle mass, which subsequently leads to skeletal muscle atrophy (4). Muscle atrophy is mainly caused by musculoskeletal injury, denervation, ligament and joint immobilization, joint inflammation, joint injuries, prolonged bed rest, sepsis, aging, cancer and glucocorticoid treatment (5-7).

In research, various model organisms of skeletal muscle atrophy have been developed, via unloading (8,9), immobilization (10), starvation (11), denervation (12) and administration of glucocorticoids (13). Among them, high doses of dexamethasone (DEXA) stimulate muscle proteolysis causing catabolic alterations in skeletal muscles (14,15). The ubiquitin-proteasome and lysosomal pathways are predominantly responsible for activation of glucocorticoid-induced protein degradation (16). Proteins involved in these pathways include atrogin-1, muscle-specific E3-ligases, muscle RING-finger protein-1 (MuRF1), cathepsin L and lysosomal enzyme (17-19). Furthermore, upregulation of myostatin is an important negative regulator of skeletal muscle mass (20), which is associated with glucocorticoid-induced catabolic muscle atrophy (21). Muscle structure and mass are deter-

---

**Key words:** dexamethasone, proteolysis, muscle atrophy, *Aureobasidium pullulans*, β-glucan
mined by the equilibrium between protein synthesis and degradation, and various proteins are involved in disused muscle atrophy (9). The mRNA expression levels of these proteins can be readily detected using reverse transcription polymerase chain reaction (RT-PCR), and RT-quantitative (q) PCR has been used to determine the efficacy of animal models of disused muscle atrophy (9,22). In addition, apoptosis (23), muscle fiber loss and destruction of the muscle antioxidant defense system (24,25) are involved in glucocorticoid-induced catabolic muscle atrophy (26). These findings suggest that glucocorticoid-induced muscle atrophy is a valuable and efficient animal model that may be used to identify agents that protect against abnormal catabolic muscle atrophy (26-29).

Oxymetholone (17β-hydroxy-2-hydroxymethylidene-17α-methyl-3-androstanone) is an orally active 17α-alkylated anabolic-androgenic steroid (30). It has a fully saturated cyclic hydrocarbon structure, which may limit the risk of hepatotoxicity (31). Oxymetholone exhibits higher anabolic activity and lower androgenic activity than methyltestosterone, testosterone and testosterone propionate (32). Oxymetholone has been approved by the US Food and Drug Administration for the treatment of anemia-associated problems that are caused by deficient red blood cell production (33). To date, oxymetholone has been used to treat various musculoskeletal disorders and as a reference drug for the production of muscle enhancers (26,33-35). However, it also exerts hepatotoxic effects (36,37) and decreases anticoagulant tolerance (38).

Numerous polysaccharides are able to activate cellular components involved in host defense mechanisms (39). β-1,3/1,6-glucan is derived from yeast cell walls and modulates numerous in vivo and in vitro activities (40). It has previously been associated with antitumor effects (41), radioprotective actions (42), increased host resistance to bacterial, viral and parasitic infections (43), and adjuvant effects (44). Extracellular polysaccharides purified from Aureobasidium pullulans SM-2001 (Polycan) (EAP) contain 13% β-1,3/1,6-glucan (45,46) as a specific component, and have exhibited favorable antitumor activities (46), anti-inflammatory activities against xylene-induced acute (47) and formalin-induced chronic (48) inflammation, potent immunomodulatory activities in cyclophosphamide-induced immunosuppressed mice (45), nephroprotective effects (49), ameliorating effects on ovalbumin-induced asthma (50), antioesthearthritic effects (51), and therapeutic effects against experimental periodontitis and associated alveolar bone losses (52), via powerful immunomodulatory, antioxidant and anti-inflammatory mechanisms.

The present study aimed to investigate whether administration of EAP prevented or improved glucocorticoid-induced catabolic muscle atrophy and to examine its possible mechanism(s) of action. EAP (100, 200 and 400 mg/kg) was administered orally, once per day for 24 days; EAP treatment was initiated 2 weeks prior to DEXA treatment. The results from the EAP-treated mice were then compared with those from mice treated with the 17α-alkylated anabolic-androgenic steroid, oxymetholone, at an oral dose of 50 mg/kg (51,52).

Materials and methods

**Test substances.** Light brown EAP powder was supplied by Glucan Corporation (Busan, South Korea) and was stored at 4°C. EAP consisted of 13% β-1, 3/1,6-glucan and 40% β-glucans, as determined using previously described analytical methods (45,46,53). Oxymetholone (50 mg tablet; Celltrion, Incheon, South Korea) was used as a reference drug; tablets were ground and were also stored at 4°C protected from light. Ground 50 mg oxymetholone tablets were dissolved at a 15 mg/ml concentration (5 mg/ml oxymetholone) in deionized distilled water. EAP was dissolved at 40 mg/ml in deionized distilled water.

**Animals and experimental design.** A total of 60 adult male SPF/ICR mice (6 weeks old), weighing 27-30 g were obtained from Orient Bio, Inc. (Seongnam, South Korea). After 10 days of acclimatization, the 48 mice that were well acclimatized in the laboratory environment (8 mice per group; a total of 6 groups) were used in the present study. The mice were maintained in polycarbonate cages (n=4-5 mice/cage) in a humidity (40-45%) and temperature (20-25°C)-controlled room under a 12-h light/dark cycle. Normal rodent pellets (cat. no. 38057; Purina Feed, Seongnam, South Korea) and water were provided ad libitum during acclimation.

Three doses of EAP (100, 200 and 400 mg/kg) were administered orally in a volume of 10 ml/kg, once a day for 24 days; EAP treatment was initiated 2 weeks prior to DEXA treatment. In addition, 50 mg/kg oxymetholone was administered orally, in a similar manner to EAP. EAP was dissolved at 10, 20 or 40 mg/ml in distilled water, and was administered orally in a volume of 10 ml/kg body weight using a zonde needle attached to a 1 ml syringe. Ground 50 mg oxymetholone tablets were also dissolved in distilled water at 15 mg/ml (5 mg/ml as oxymetholone) and administered orally at 10 ml/kg, which was equivalent to 150 mg/kg (50 mg/kg as oxymetholone). The dosage of oxymetholone was selected based on previous efficacy tests in mice (26,33-35). Doses of 100, 200 and 400 mg/kg EAP were selected based on previously reported in vivo efficacy tests of EAP (45,46). In the present study, catabolic muscle atrophy was initiated by subcutaneous treatment with 1 mg/kg DEXA, once a day for 10 days, according to previously reported methods (16,26). Water-soluble DEXA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was dissolved in saline at 1.5 mg/ml (0.1 mg/ml DEXA) and was subcutaneously injected into the cervical dorsal region in a volume of 10 ml/kg, equivalent to 15 mg/kg (1 mg/kg as DEXA itself). An equal volume of deionized distilled water, instead of oxymetholone or EAP, was orally administered in the DEXA control and intact vehicle groups, and an equal volume of saline, instead of DEXA, was injected subcutaneously into the intact vehicle control group. The present study was conducted in accordance with international regulations of the usage and welfare of laboratory animals, and was approved by the Institutional Animal Care and Use Committee, Daegu Haany University (Gyeongsan, South Korea; approval no. DHU2016-051, May 27, 2016).

**Body weight measurements.** Body weight (g) was measured 1 day prior to, the day of, and 1, 7, 14, 19, 23 and 24 days after treatment administration using an electronic balance (Precisa Gravimetrics AG, Dietikon, Switzerland). The gain in body weight during the 14 days of pretreatment, the 10 days of DEXA treatment and the total 24-day treatment periods was measured to decrease individual differences, according to equation 1, where BW indicates body weight:
During 14 days of pretreatment = BW at 14 days after initial administration - BW at first administration (Eq. 1a).

During 10 days of DEXA treatment = BW on the last day of DEXA treatment - BW on the first day of DEXA treatment* (Eq. 1b). *A total of 2 weeks after pretreatment.

During total 24 days of treatment = BW at sacrifice - BW on the first day of pretreatment (Eq. 1c).

**Calf and gastrocnemius muscle thickness measurements.** The thickness of the left hind calf was measured 1 day prior to, the day of, and 1, 7, 14, 19, 23 and 24 days after treatment administration using electronic digital calipers (Mitutoyo, Tokyo, Japan), similar to previous studies (26,35). Gastrocnemius muscle thickness in the left hind limb was measured following muscle exposure after sacrifice (all mice were sacrificed at the end of the 24-day period; liver, kidney, pancreas, calf muscle mass and gastrocnemius muscle tissues were collected following sacrifice), in order to decrease variability from the surrounding tissues. Gastrocnemius muscle thickness was measured according to the method used to measure calf thickness; alterations in calf thickness (mm) during 14 days of pretreatment, 10 days of DEXA treatment and the total 24-day treatment period were measured to reduce individual differences, according to equation 2, where CT indicates calf thickness:

\[
\text{During 14 days of pretreatment = CT at 14 days after initial administration - CT at first administration (Eq. 2a).}
\]

\[
\text{During 10 days of DEXA treatment = CT at the last day of DEXA treatment - CT at the first day DEXA treatment (Eq. 2b). *A total of 2 weeks after pretreatment.}
\]

\[
\text{After 24 days of treatment = CT at sacrifice - CT on the first day of pretreatment (Eq. 2c).}
\]

**Calf muscle strength measurements.** A total of 1 h after the last dose of oxymethalone, vehicle or EAP was administered (10 days after the initial DEXA treatment), the calf muscle strengths of individual mice were measured as tensile strengths (10 days after the initial DEXA treatment)* (Eq. 2c). A total of 14 days after initial DEXA treatment (Eq. 2a).

**Gastrocnemius muscle weight measurements.** After gastrocnemius muscle thickness was measured following sacrifice, the gastrocnemius muscles were separated carefully from the tibia and fibula bones. The weights of individual gastrocnemius muscles were measured in g (absolute wet-weights) using an electronic balance, and to reduce the differences from individual body weights, relative weights (% of body weights) were calculated according to body weight at sacrifice and absolute weight, following equation 3.

\[
\text{Relative muscle mass (% of body weight) = } \frac{\text{absolute muscle mass}}{\text{body weight at sacrifice}} \times 100 \text{ (Eq. 3)}
\]

**Serum biochemistry.** To obtain sera for biochemical analysis, blood samples were collected on the day of sacrifice using a separation tube, and were then centrifuged at 600 x g for 10 min at ambient temperature. Separated serum samples were stored at -150˚C in an ultra-deep freezer until further analysis. Serum creatine, creatine kinase (CK) and lactate dehydrogenase (LDH) levels were measured using an auto analyzer (Dri-Chem NX500i; FUJIFILM Medical Systems U.S.A., Inc., Stamford, CT, USA).

**Antioxidant defense systems.** Following muscle mass measurements, gastrocnemius muscles were separated and the malondialdehyde (MDA), glutathione (GSH) and reactive oxygen species (ROS) contents, and superoxide dismutase (SOD) and catalase (CAT) enzyme activities were assessed in individual muscles. Separated gastrocnemius muscles were weighed and homogenized in ice-cold 0.01 M Tris-HCl (pH 7.4), after which they were centrifuged at 12,000 x g for 15 min at ambient temperature, as described previously (54). Muscle tissue homogenates were stored at -150˚C in an ultra-deep freezer until analysis. The degree of gastrocnemius muscle lipid peroxidation was measured by assessing MDA values using the thiobarbituric acid test at 525 nm using a UV/vis spectrometer (Optizen POP; Mecasys Co., Ltd., Daejeon, South Korea) (55). The total protein contents were measured using the Lowry method (56), whereas bovine serum albumin (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used as a standard. ROS level analyses were performed using 2’·7’-dichlorofluorescein diacetate fluorescent dye as a probe and fluorescence density was measured at 490/520 nm according to the manufacturer’s protocol (Cellular Reactive Oxygen Species Detection assay kit; ab113851; Abcam, Cambridge, MA, USA); the measured optical density values were corrected to the protein contents of samples and were expressed as RFU/µg† protein (57). In addition, prepared homogenates were mixed with 0.1 ml 25% trichloroacetic acid (EMD Millipore, Billerica, MA, USA) and were then centrifuged at 800 x g for 40 min at 4˚C. GSH contents were measured at 412 nm using 2-nitrobenzoic acid (Sigma-Aldrich; Merck KGaA), and were expressed as mg/g tissue (58). H₂O₂ decomposition in the presence of CAT was estimated at 240 nm (59). CAT activity was defined as the amount of enzyme required to decompose 1 nM H₂O₂ per min, at 25°C and pH 7.8, and the results are expressed as U/mg¹ protein. Furthermore, SOD activity was measured at 560 nm according to a protocol previously described by Sun et al (60), and was expressed as U/mg² protein. One unit of SOD enzymatic activity is equal to the amount of enzyme that diminishes the initial absorbance of nitroblue tetrazolium by 50% during 1 min.

**RT-qPCR.** Total RNA was extracted from gastrocnemius muscles using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to previous studies (9,26,35,61). The RNA concentration and quality were determined using a CFX96™ Real-Time PCR Detection system using iTaq™ SYBR-Green (both from Bio-Rad Laboratories, Inc., Hercules, CA, USA). The samples were treated with recombinant DNase I (DNA-free DNA removal kit; Ambion, Austin, TX, USA) to remove possible DNA contamination. RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The PCR cycling
conditions were as follows: Initial pre-denaturation of 95°C for 1 min, denaturation for 15 sec, annealing of 55-65°C for 20 sec and extension of 72°C for 30 sec. A total of 50 cycles were performed. 18S ribosomal RNA was used as an internal control. PCR primer sequences are listed in Table I. For quantitative analysis, the intact control muscle tissue was used as the control, and the relative expression of Atrogin-1, MuRF 1, PI3K p85α, Akt1, Adenosine A1R, TRPV4, Myostatin and SIRT1 was calculated using the 2-ΔΔCt method (62).

**Histopathology.** Samples from gastrocnemius muscles were separated and fixed in 10% neutral buffered formalin, embedded in paraffin wax, sectioned (3-4 µm), and stained with Sirius red for collagen fibers or hematoxylin and eosin for general histopathology (63,64). Histopathological profiles were observed under a light microscope (Eclipse 80i; Nikon Corporation, Tokyo, Japan). Mean muscle fiber diameters (µm/fiber) and collagen fiber-occupied regions (%/mm²) in muscle bundles were calculated using an automated image analyzer (iSolution FL, version 9.1; Brooke Anco Corporation, Cicero, NY, USA) in gastrocnemius muscle samples, according to previous studies (9,15,21,26,35,63) with some modifications.

**Immunohistochemistry.** Following deparaffinization of gastrocnemius muscle histological sections, citrate buffer antigen retrieval was conducted as previously described (26,35,65). Briefly, a staining dish containing 10 mM citrate buffer (pH 6.0) was preheated at 95-100°C in a water bath. Slides were immersed in the staining dish and incubated for 20 min prior to turning off the water bath. The staining dish was placed at room temperature and the slides were allowed to cool for 20 min. Subsequently, sections were immunostained using the avidin-biotin complex (ABC) method, to detect caspase-3, poly (ADP-ribose) polymerase (PARP), nitrotyrosine, 4- hydroxynonenal (4-HNE), inducible nitric oxide synthase (iNOS) and myostatin expression (Table II) according to previous studies (26,35). Briefly, endogenous peroxidase activity was blocked by incubation in methanol and 0.3% H₂O₂ for 30 min at ambient temperature, and non-specific binding was blocked with normal horse serum blocking solution (1:100; Vector Laboratories, Inc., Burlingame, CA, USA) for 1 h at ambient temperature in a humidified chamber. Slides were incubated with primary antibodies (Table II) overnight at 4°C in a humidified chamber, and were then incubated with biotinylated universal secondary antibody [1:50; Vectastain Elite ABC kit (PK-6200); Vector Laboratories, Inc.] and ABC reagents (1:50; Vectastain Elite ABC kit, Vector Laboratories, Inc.) for 1 h at room temperature in a humidified chamber. Finally, sections were treated with a peroxidase substrate kit (Vector Laboratories, Inc.) for 3 min at room temperature. All of the sections were rinsed in 0.01 M PBS three times between steps. Cells or muscle fibers that exhibited >20% immunoreactivity with each antibody were considered positive, and the mean numbers of caspase-3, PARP, nitrotyrosine, 4-HNE, iNOS and myostatin-immunoreactive fibers, as dispersed in 1 mm² of muscle bundles, were counted using an image analysis process described by Kim et al (26,35) with

---

**Table I. Oligonucleotides for quantitative polymerase chain reaction used in the present study.**

| Target          | Sequences (5’-3’)                          | Size (bp) | Gene ID |
|-----------------|--------------------------------------------|-----------|---------|
| Atrogin-1       | F: CAGCTTTCGAGCCGCACTTC R: GGCACTGAGAAGTCCAGTC | 244       | 67731   |
| MuRF 1          | F: GACAGCTGAGCTTTAAGCA R: GCTGAGTCCAGCTTGAAG | 194       | 433766  |
| PI3K p85α       | F: GCCAGTTGTCATTTGTTGTTG R: ACCACACAGGAACTTCA | 236       | 18078   |
| Akt1            | F: ATGAACGAGCATGCCATGTTG T: TTGAGCCAATAAAGGTCCAT | 116       | 11651   |
| Adenosine A1R   | F: TGTTCCACGGGCTTCAC R: TAATGGACTAGACTGACTTGTA | 155       | 11539   |
| TRPV4           | F: CAGGACCTCTGGAAAGTGC R: AAGACGCTGCTGGACACCA | 165       | 63873   |
| Myostatin       | F: CCTCCACTCGGAACTGA R: AAGACGCTCAGCTGTGTCATC | 185       | 17700   |
| SIRT1           | F: TTCACATCCGTGTTGGG T: TGAGGCCCAGTGCTAACC | 175       | 93759   |
| 18S ribosomal RNA| F: AGCCTGAGAAGACGGCTACC R: TCCAAAGATCCAATACGAG | 252       | 19791   |

A1R, A1 receptor; Akt1, AKT serine/threonine kinase 1; F, forward; MuRF1, muscle RING-finger protein-1; PI3K, phosphatidylinositol 3-kinase; R, reverse; SIRT1, sirtuin 1; TRPV4, transient receptor potential cation channel subfamily V member 4.
some modifications. The histopathologist was blinded to the group distribution when performing the analysis.

Statistical analysis. All numerical values are expressed as the means ± SD of 8 mice. Multiple comparison tests for different dose groups were conducted. Variance homogeneity was examined using the Levene test (66). If the Levene test indicated no significant deviation from variance homogeneity, data were analyzed by one-way analysis of variance followed by least-significant differences multi-comparison test to determine which pairs of group comparisons were significantly different. In cases where significant deviations from variance homogeneity were observed with the Levene test, the non-parametric Kruskal-Wallis H-test was used. When a significant difference was observed with the Kruskal-Wallis H test, the Mann-Whitney U test was conducted to determine the specific pairs of group comparisons that were significantly different. Statistical analyses were conducted using SPSS 14K for Windows software (SPSS Inc., Chicago, IL, USA) (67). Statistical significances were set at P<0.01 and P<0.05. Percent changes between intact vehicle and DEXA control groups were calculated to assess the severities of catabolic muscle atrophy.

Table II. Primary antibodies and detection kits used in the present study.

| Antibodies or detection kits | Cat. no. | Source | Dilution |
|-----------------------------|----------|--------|----------|
| Primary antibodies\(^a\)   |          |        |          |
| Anti-cleaved caspase-3 (Asp175) polyclonal antibody | 9661     | Cell Signaling Technology Inc. (Danvers, MA, USA) | 1:400 |
| Anti-cleaved PARP (Asp214) specific antibody | 9545     | Cell Signaling Technology Inc. | 1:100 |
| Anti-4-hydroxynonenal polyclonal antibody | Ab46545 | Abcam (Cambridge, UK) | 1:100 |
| Anti-nitrotyrosine polyclonal antibody | 06-284   | EMD Millipore (Billerica, CA, USA) | 1:200 |
| Anti-nitric oxide synthase 2 (N-20) polyclonal antibody | sc-651   | Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) | 1:100 |
| Anti-GDF8/Myostatin antibody | Ab71808  | Abcam | 1:50 |
| Detection kits              |          |        |          |
| Vectastain Elite ABC kit    | PK-6200  | Vector Laboratories, Inc. (Burlingame, CA, USA) | 1:50 |
| Peroxidase substrate kit    | SK-4100  | Vector Laboratories, Inc. | 1:50 |

\(^a\)All antibodies were diluted in 0.01 M phosphate-buffered saline in this experiment. ABC, avidin-biotin complex; GDF8, growth differentiation factor 8; PARP, poly (ADP-ribose) polymerase.

Table III. Alterations in body weight in mice with DEXA-induced muscle atrophy.

| Group          | 14 days of test material pretreatment | 10 days of DEXA treatment | Total 24 days of treatment |
|----------------|--------------------------------------|---------------------------|---------------------------|
|                | Weight gain (g)                      |                           |                           |
| Controls       |                                      |                           |                           |
| Intact         | 5.74±0.63                            | 1.30±0.34                 | 3.23±0.96                 |
| DEXA           | 5.63±0.49                            | -5.50±0.81\(^a\)         | -4.00±0.63\(^b\)         |
| Reference      |                                      |                           |                           |
| Oxymetholone   | 5.43±0.56                            | -1.19±0.47\(^c\)         | 0.20±0.66\(^h,d\)        |
| EAP-treated    |                                      |                           |                           |
| 400 mg/kg      | 5.68±0.58                            | -1.49±0.73\(^c\)         | 0.34±1.14\(^h,d\)        |
| 200 mg/kg      | 5.71±0.41                            | -2.58±0.52\(^c\)         | -0.73±0.55\(^d\)         |
| 100 mg/kg      | 5.61±0.62                            | -3.24±0.95\(^c\)         | -1.44±0.81\(^d\)         |

Values are expressed as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water. \(^a\)P<0.01 compared with the intact control group, as determined by MW test. \(^b\)P<0.01 compared with the intact control group, as determined by LSD test. \(^c\)P<0.01 compared with the DEXA control group, as determined by MW test. \(^d\)P<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from Aureobasidium pullulans SM-2001; LSD, least-significant difference; MW, Mann Whitney U.
induced, and the percent changes between the DEXA control and test material-treated mice were calculated, in order to understand the efficacy of the test substances according to the following equations 4 and 5:

\[
\text{Percentage change compared to the intact vehicle control group} (\%) = \frac{\text{Data of DEXA control} - \text{Data of intact vehicle control}}{\text{Data of intact vehicle control}} \times 100 \quad (\text{Eq. 4}).
\]

\[
\text{Percentage change compared to the DEXA control group} (\%) = \frac{\text{Data of test material treated mice} - \text{Data of DEXA control}}{\text{Data of DEXA control}} \times 100 \quad (\text{Eq. 5}).
\]

**Results**

**Alterations in body weight.** Significant decreases (P<0.01) in body weight were demonstrated in the DEXA control mice compared with in the intact control mice from 5 days after initial DEXA treatment to sacrifice. Accordingly, body weight during the 10 days of DEXA treatment, and after the total 24-day experimental period, was significantly decreased (P<0.01) in the DEXA control mice compared with in the intact vehicle control group. However, these decreases in body weight were significantly inhibited (P<0.01) by treatment with oxymetholone and all three doses of EAP (100, 200 and 400 mg/kg) from 5 days after initial DEXA treatment to sacrifice. In addition, body weight after 10 days of DEXA treatment, and after the total 24-day experimental period, was significantly increased (P<0.01) in the oxymetholone- and EAP-treated mice compared with in the DEXA control group. Anyway, no test material treatment-related alterations in body weight were detected compared with intact vehicle or DEXA control mice in this experiment. Treatment with EAP (100, 200 and 400 mg/kg) exhibited...
dose-dependent inhibitory effects on DEXA-induced decreases in body weight, in particular 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in body weight, which were comparable with the effects of 50 mg/kg oxymetholone (Table III and Fig. 1).

Effects on calf thickness. Significant decreases (P<0.01) in calf thickness were demonstrated in the DEXA control mice compared with in the intact control mice from 19 days after the initial test substance administration to the day of sacrifice (dotted arrow). However, these decreases in calf thickness were significantly and dose-dependently inhibited by treatment with all three doses of EAP (400, 200 and 100 mg/kg) from 5 days after the initial DEXA treatment (arrowhead). In addition, 50 mg/kg oxymetholone-treated mice also exhibited significant increases in calf thickness from 5 days after the initial DEXA treatment compared with in the DEXA control mice (arrowhead). EAP (400 mg/kg) exhibited favorable inhibitory activities on DEXA-induced decreases in calf thickness, as comparable to those of oxymetholone (50 mg/kg). Data are presented as the mean ± standard deviation of 8 mice. Day -1 and 24 indicates 1 day prior to initial administration of test materials and the day of sacrifice, respectively. Day 0 indicates initiation of test material administration, at 2 weeks prior to initial DEXA treatment. All animals were fasted overnight prior to initial administration of test materials and sacrifice (arrows). *P<0.01 compared with the intact control group, as determined by LSD test. †P<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from Aureobasidium pullulans SM-2001; LSD, least-significant difference. Results were significant at 24 days.
Dose-dependent inhibitory effects on DEXA-induced decreases in gastrocnemius muscle weights; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in gastrocnemius muscle thickness, which were comparable with the effects of oxymetholone (50 mg/kg). Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in deionized distilled water. *P<0.01 compared with the intact control group, as determined by LSD test. \(^\text{b}\)P<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from Aureobasidium pullulans SM-2001; LSD, least-significant difference.

**Effects on gastrocnemius muscle mass.** Significant decreases (P<0.01) in relative weights and absolute wet weights of gastrocnemius muscle mass were demonstrated in the DEXA control mice compared with in the intact vehicle control mice. However, significant increases (P<0.01) in gastrocnemius muscle mass were observed in the oxymetholone and all three doses of EAP compared with in the DEXA control group. EAP (100, 200 and 400 mg/kg) exhibited dose-dependent inhibitory effects on DEXA-induced decreases in gastrocnemius muscle thickness. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in calf muscle strength; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in calf muscle strength, which were comparable with the effects of oxymetholone (50 mg/kg). Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in deionized distilled water. *P<0.01 compared with the intact control group, as determined by LSD test. \(^\text{b}\)P<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from Aureobasidium pullulans SM-2001; LSD, least-significant difference.

**Effects on calf muscle strength.** Significant decreases (P<0.01) in the tensile strength of calf muscles were demonstrated in the DEXA control mice compared with in the intact vehicle control mice. However, significant increases (P<0.01) in calf muscle strength were observed in the oxymetholone-treated and 200 and 400 mg/kg EAP-treated mice compared with in the DEXA control group. In addition, 100 mg/kg EAP-treated mice exhibited non-significant increases in calf muscle strength compared with in the DEXA control mice. EAP (400, 200 and 100 mg/kg) exhibited clear dose-dependent inhibitory effects on DEXA-induced decreases in calf muscle strength; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in calf muscle strength, which were comparable with the effects of oxymetholone (50 mg/kg). Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in deionized distilled water. *P<0.01 compared with the intact control group, as determined by LSD test. \(^\text{b}\)P<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from Aureobasidium pullulans SM-2001; LSD, least-significant difference.

**Effects on gastrocnemius muscle thickness following muscle exposure.** Significant decreases (P<0.01) in gastrocnemius muscle thickness following muscle exposure were observed in the
mice compared with in the DEXA control group. In addition, 100 mg/kg EAP-treated mice exhibited non-significant increases in calf muscle strength compared with in the DEXA control mice. EAP (100, 200 and 400 mg/kg) exhibited dose-dependent inhibitory effects on DEXA-induced decreases in calf muscle strength; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in calf muscle strength, which were comparable with the effects of 50 mg/kg oxymetholone (Fig. 6).

Effects on serum biochemistry. Significant increases (P<0.01) in serum CK and creatine levels, and decreases in serum LDH levels, were demonstrated in the DEXA control mice compared with in the intact vehicle control mice. However, significant decreases (P<0.05) in serum CK and creatine levels were observed in oxymetholone- and EAP-treated mice compared with in the DEXA control group, alongside significant increases (P<0.05) in serum LDH levels. EAP (100, 200, and 400 mg/kg) exhibited dose-dependent inhibitory effects on DEXA-induced increases

Table V. Alterations in the serum biochemistry of mice with DEXA-induced muscle atrophy.

| Group                  | Creatine (mg/dl) | Creatine kinase (IU/l) | LDH (IU/l)    |
|------------------------|------------------|------------------------|---------------|
| Controls               |                  |                        |               |
| Intact                 | 0.33±0.06        | 83.63±19.40            | 647.25±131.86 |
| DEXA                   | 0.85±0.11        | 274.13±51.85           | 163.25±47.63  |
| Reference              |                  |                        |               |
| Oxymetholone           | 0.45±0.05        | 146.50±18.15           | 304.13±71.06  |
| EAP-treated            |                  |                        |               |
| 400 mg/kg              | 0.49±0.09        | 152.88±14.26           | 294.00±42.81  |
| 200 mg/kg              | 0.57±0.10        | 176.63±15.40           | 264.25±53.73  |
| 100 mg/kg              | 0.66±0.12        | 210.75±29.35           | 242.50±29.24  |

Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water. aP<0.01 compared with the intact control group, as determined by LSD test. bP<0.01 compared with the intact control group, as determined by MW test. cP<0.05 compared with the intact control group, as determined by LSD test. dP<0.1 compared with the DEXA control group, as determined by LSD test. eP<0.01 and fP<0.05 compared with the DEXA control group, as determined by MW test. gP<0.05 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference; MW, Mann Whitney U.

Table VI. Alterations in the gastrocnemius muscle antioxidant defense system in mice with DEXA-induced muscle atrophy.

| Group                  | Malondialdehyde (nM/mg protein) | Reactive oxygen species (RFU/µg protein) | Glutathione (nM/mg protein) | Superoxide dismutase (nM/min/mg protein) | Catalase (U/mg protein) |
|------------------------|---------------------------------|----------------------------------------|----------------------------|------------------------------------------|-------------------------|
| Controls               |                                 |                                        |                            |                                          |                         |
| Intact                 | 1.84±0.76                       | 22.12±10.46                            | 0.64±0.15                  | 34.14±10.58                              | 7.08±2.11               |
| DEXA                   | 8.32±1.11                       | 67.40±12.82                            | 0.16±0.07                  | 11.19±1.97                               | 1.84±0.24               |
| Reference              |                                 |                                        |                            |                                          |                         |
| Oxymetholone           | 4.44±1.05                       | 31.92±11.89                            | 0.37±0.09                  | 21.51±4.42                               | 3.64±0.70               |
| EAP-treated            |                                 |                                        |                            |                                          |                         |
| 400 mg/kg              | 4.48±1.20                       | 31.89±10.67                            | 0.38±0.10                  | 20.81±4.57                               | 3.56±0.83               |
| 200 mg/kg              | 5.81±0.90                       | 37.31±10.21                            | 0.34±0.12                  | 18.94±4.46                               | 3.12±0.49               |
| 100 mg/kg              | 6.42±0.76                       | 45.19±12.22                            | 0.29±0.08                  | 17.52±2.30                               | 2.70±0.52               |

Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water. aP<0.01 compared with the intact control group, as determined by LSD test. bP<0.01 compared with the intact control group, as determined by MW test. cP<0.01 compared with the DEXA control group, as determined by LSD test. dP<0.01 compared with the DEXA control group, as determined by MW test. eP<0.05 compared with the intact control group, as determined by LSD test. fP<0.05 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference; MW, Mann Whitney U.
Table VII. Alterations in gastrocnemius muscle mRNA expression in mice with DEXA-induced muscle atrophy.

| Target      | Controls                      | Reference                    | EAP-treated mice (mg/kg) |
|-------------|-------------------------------|------------------------------|--------------------------|
|             | Intact DEXA                   | Oxymetholone                 | 400 200 100              |
| Atrogin-1   | 0.99±0.07 4.90±0.67<sup>a</sup> | 2.20±0.44<sup>b</sup>       | 2.29±0.44<sup>b</sup>    |
| MuRF1       | 1.08±0.22 6.15±0.97<sup>c</sup>| 2.96±0.54<sup>a</sup>       | 3.05±0.61<sup>c</sup>    |
| PI3K p85α   | 1.03±0.13 0.62±0.09<sup>a</sup>| 1.13±0.39<sup>b</sup>       | 1.11±0.33<sup>b</sup>    |
| Akt1        | 1.01±0.06 0.52±0.07<sup>c</sup>| 0.85±0.10<sup>d</sup>       | 0.85±0.09<sup>d</sup>    |
| A1R         | 1.03±0.14 0.49±0.12<sup>c</sup>| 0.86±0.06<sup>c</sup>       | 0.86±0.11<sup>d</sup>    |
| TRPV4       | 1.09±0.10 0.35±0.08<sup>a</sup>| 0.65±0.10<sup>d</sup>       | 0.68±0.15<sup>c,d</sup>  |
| Myostatin   | 1.01±0.09 6.88±0.89<sup>a</sup>| 3.16±0.73<sup>b</sup>       | 3.17±0.59<sup>b</sup>    |
| SIRT1       | 1.01±0.18 10.49±2.97<sup>a</sup>| 3.66±1.13<sup>b</sup>       | 3.49±1.00<sup>b</sup>    |

Data are presented as the mean ± standard deviation of 8 mice. Expression levels were normalized to 18S ribosomal RNA expression. Oxymetholone was orally administered at 50 mg/kg levels, dissolved in distilled water. *P<0.01 compared with the intact control group, as determined by MW test. †P<0.01 compared with the DEXA control group, as determined by MW test. ‡P<0.01 compared with the intact control group, as determined by LSD test. §P<0.05 compared with the intact control group, as determined by MW test. A1R, adenosine A1 receptor; Akt1, AKT serine/threonine kinase 1; DEXA, dexamethasone; EAP, extracellular polysaccharides purified from Aureobasidium pullulans SM-2001; LSD, least-significant difference; MuRF1, muscle RING-finger protein-1; MW, Mann Whitney U; PI3K, phosphatidylinositol 3-kinase; SIRT1, sirtuin 1; TRPV4, transient receptor potential cation channel subfamily V member 4.

in serum CK and creatine levels, and decreases in serum LDH levels. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on serum CK and creatine level elevations, and decreases in serum LDH levels, which were comparable with the effects of 50 mg/kg oxymetholone (Table V).

**Effects on gastrocnemius muscle antioxidant defense systems**

**Alterations in muscle MDA levels.** Significant increases (>0.01) in MDA levels were observed in the DEXA control group compared with in the intact control group. However, the elevations in MDA levels were significantly (>0.01) and dose-dependently decreased following treatment with EAP. Gastrocnemius muscle lipid peroxidation in oxymetholone-treated mice was also significantly decreased (<0.01) compared with in the control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in muscle lipid peroxidation, which were comparable with the effects of 50 mg/kg oxymetholone (Table VI).

**Alterations in muscle ROS content.** Significant increases (>0.01) in muscle ROS content were observed in the DEXA control group compared with in the intact control group. However, elevated ROS levels were significantly and dose-dependently decreased (>0.01) following treatment with EAP. In addition, gastrocnemius muscle ROS levels were significantly (>0.01) inhibited in 50 mg/kg oxymetholone-treated mice compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced muscle ROS elevations, which were comparable with the effects of oxymetholone (Table VI).

**Alterations in muscle GSH content.** Significant decreases (>0.01) in the levels of the endogenous antioxidant, GSH, were detected in the DEXA control group compared with in the intact control group. However, these decreases in muscle GSH were significantly (<0.01) inhibited following 24 days of oral treatment with oxymetholone, and 100, 200 and 400 mg/kg EAP. EAP increased gastrocnemius muscle GSH content in a dose-dependent manner compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in muscle GSH content, which were comparable with the effects of oxymetholone (Table VI).

**Alterations in muscle SOD activity.** Significant decreases (>0.01) in the activity levels of the endogenous antioxidant enzyme, SOD, were detected in the DEXA control group compared with in the intact control group. However, significant increases (>0.01) in SOD activity were observed in oxymetholone-treated, and 100, 200 and 400 mg/kg EAP-treated mice compared with in the DEXA control mice. EAP exerted dose-dependent increases on SOD activity in gastrocnemius muscles compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in SOD activity levels, which were comparable with the effects of oxymetholone (Table VI).

**Alterations in muscle CAT activity.** Significant decreases (>0.01) in the activity levels of the endogenous antioxidant enzyme, CAT, were detected in the DEXA control group compared with in the intact control group. However, these decreases in muscle CAT activity were significantly and dose-dependently inhibited (>0.01) following 24 days of oral treatment with EAP. Gastrocnemius muscle CAT activity levels in 50 mg/kg oxymetholone-treated mice were also significantly increased (>0.01) compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in
muscle CAT activity levels, which were comparable with the effects of 50 mg/kg oxymetholone (Table VI).

**Effects on gastrocnemius muscle mRNA expression.** Significant alterations (P<0.01) in the mRNA expression levels of atrogin-1, MuRF1, PI3K, Akt1, A1R, TRPV4, myostatin and SIRT1 were detected in the gastrocnemius muscles of the DEXA control group compared with in the intact control group. However, these alterations in muscle atrogin-1, MuRF1, PI3K, Akt1, A1R, TRPV4, myostatin and SIRT1 expression were significantly reversed (P<0.05), in a dose-dependent manner, by treatment with EAP. In addition, the mRNA expression levels of atrogin-1, MuRF1, PI3K, Akt1, A1R, TRPV4, myostatin and SIRT1 in gastrocnemius muscle tissues, were significantly reversed in 50 mg/kg oxymetholone-treated mice (P<0.01) compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable activities on DEXA-induced decreases in mean muscle fiber diameter and increases in collagen fiber-occupied region percentages in muscle bundles, which were comparable with the effects of oxymetholone (50 mg/kg). (A) Deionized distilled water-administered and saline-treated mice (intact vehicle control group). (B) Deionized distilled water-administered and DEXA-treated control mice (DEXA control group). (C) Oxymetholone (50 mg/kg)-administered and DEXA-treated reference mice (oxymetholone group). (D) EAP (400 mg/kg)-administered and DEXA-treated experimental mice (EAP400 group). (E) EAP (200 mg/kg)-administered and DEXA-treated experimental mice (EAP200 group). (F) EAP (100 mg/kg)-administered and DEXA-treated experimental mice (EAP100 group). Scale bars=40 μm. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001.

Figure 7. Representative gastrocnemius muscle histology. Marked catabolic muscular atrophy-associated alterations, including microvacuolation, reduced muscle fibers and focal fibrosis in muscle bundles were induced by treatment with DEXA; accordingly, significant decreases in mean muscle fiber diameters and increases in collagen fiber-occupied region percentages in muscle bundles were detected in the DEXA control mice compared with in the intact control mice. However, these DEXA treatment-associated catabolic atrophic alterations to gastrocnemius muscles were significantly and dose-dependently decreased following treatment with EAP. In addition, the muscular atrophic alterations were significantly reduced in 50 mg/kg oxymetholone-treated mice compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in mean muscle fiber diameter and increases in collagen fiber-occupied region percentages in muscle bundles, which were comparable with the effects of oxymetholone (50 mg/kg). (A) Deionized distilled water-administered and saline-treated mice (intact vehicle control group). (B) Deionized distilled water-administered and DEXA-treated control mice (DEXA control group). (C) Oxymetholone (50 mg/kg)-administered and DEXA-treated reference mice (oxymetholone group). (D) EAP (400 mg/kg)-administered and DEXA-treated experimental mice (EAP400 group). (E) EAP (200 mg/kg)-administered and DEXA-treated experimental mice (EAP200 group). (F) EAP (100 mg/kg)-administered and DEXA-treated experimental mice (EAP100 group). Scale bars=40 μm. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001.
Table VIII. Alterations in gastrocnemius muscle histomorphometry in mice with DEXA-induced muscle atrophy.

| Variable                        | Groups                                      |
|---------------------------------|---------------------------------------------|
|                                 | Intact | DEXA | Oxymetholone | 400 | 200 | 100 |
| General histomorphometry        |        |      |              |     |     |     |
| Fiber diameter (µm)             | 51.36±10.37 | 23.35±5.26 | 38.03±6.72<sup>b</sup> | 37.39±7.30<sup>b</sup> | 34.77±6.65<sup>b</sup> | 31.87±4.30<sup>abc</sup> |
| Collagen (%)                    | 4.09±1.71 | 31.96±4.71<sup>d</sup> | 16.72±3.30<sup>ae</sup> | 15.93±4.62<sup>de</sup> | 19.36±3.02<sup>de</sup> | 23.57±5.64<sup>df</sup> |
| Immunohistomorphometry (fibers/mm²) |        |      |              |     |     |     |
| Caspase-3                       | 2.13±2.53 | 41.13±10.45<sup>e</sup> | 20.88±5.03<sup>b</sup> | 19.00±2.83<sup>b</sup> | 23.63±5.26<sup>b</sup> | 28.00±6.55<sup>abc</sup> |
| PARP                            | 4.88±2.59 | 75.00±12.94<sup>e</sup> | 32.13±10.25<sup>b</sup> | 31.25±10.94<sup>b</sup> | 38.63±14.34<sup>b</sup> | 48.50±12.04<sup>bc</sup> |
| Nitrotyrosine                   | 5.63±2.67 | 67.75±12.37<sup>e</sup> | 34.63±13.09<sup>b</sup> | 31.38±14.51<sup>b</sup> | 38.25±15.18<sup>b</sup> | 46.00±13.31<sup>bc</sup> |
| 4-HNE                           | 3.75±1.91 | 75.38±11.67<sup>d</sup> | 42.25±10.50<sup>b</sup> | 40.38±10.14<sup>b</sup> | 45.75±10.98<sup>b</sup> | 53.50±10.60<sup>bc</sup> |
| iNOS                            | 7.63±2.77 | 50.25±11.85<sup>d</sup> | 20.38±4.63<sup>de</sup> | 16.25±3.54<sup>de</sup> | 27.63±7.85<sup>de</sup> | 32.75±8.76<sup>de</sup> |
| Myostatin                       | 1.13±0.83 | 51.88±11.15<sup>d</sup> | 21.75±4.83<sup>de</sup> | 20.38±5.40<sup>de</sup> | 32.75±4.98<sup>de</sup> | 36.38±7.63<sup>de</sup> |

Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water. <sup>a</sup>P<0.01 compared with the intact control group, as determined by LSD test. <sup>b</sup>P<0.01 and <sup>c</sup>P<0.05 compared with the DEXA control group, as determined by LSD test. <sup>d</sup>P<0.01 compared with the intact control group, as determined by MW test. <sup>e</sup>P<0.01 and <sup>f</sup>P<0.05 compared with the DEXA control group, as determined by MW test. 4-HNE, 4-hydroxynonenal; DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference; MW, Mann Whitney U; iNOS, inducible nitric oxide synthase; PARP, cleaved poly (ADP-ribose) polymerase.

**Effects on gastrocnemius muscle histopathology.** Marked alterations associated with catabolic muscle atrophy, including focal fibrosis in muscle bundles, microvacuolation and diminished muscle fibers, were induced by treatment with DEXA in the control mice. Accordingly, significant decreases (P<0.01) in mean muscle fiber diameters and increases in collagen fiber-occupied region percentages in muscle bundles were detected in the DEXA control mice compared with in the intact control mice. However, these DEXA treatment-associated catabolic alterations were significantly (P<0.05) and dose-dependently decreased following treatment with EAP. The muscle atrophy-associated alterations were also significantly inhibited (P<0.01) in 50 mg/kg oxymetholone-treated mice compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in mean muscle fiber diameters and increases in collagen fiber-occupied regions in muscle bundles, which were comparable with the effects of oxymetholone (Table VIII and Fig. 7).

**Effects on gastrocnemius muscle immunohistochemistry**

**Alterations in caspase-3-immunolabelled muscle fibers.** Significant increases (P<0.01) in caspase-3 (apoptotic marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P<0.01) these DEXA-induced increases in caspase-3-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P<0.01) the number of caspase-3-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in caspase-3 immunoreactivity, which were comparable with the effects of oxymetholone (Table VIII and Fig. 8).

**Alterations in PARP-immunolabelled muscle fibers.** Significant increases (P<0.01) in PARP (apoptotic marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P<0.01) these DEXA-induced increases in PARP-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P<0.01) the number of PARP-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in PARP immunoreactivity, which were comparable with the effects of oxymetholone (Table VIII and Fig. 8).

**Alterations in nitrotyrosine-immunolabelled muscle fibers.** Significant increases (P<0.01) in nitrotyrosine (iNOS-associated oxidative stress marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P<0.01) these DEXA-induced increases in the number of nitrotyrosine-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P<0.01) the number of nitrotyrosine-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P<0.01) these DEXA-induced increases in the number of nitrotyrosine-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P<0.01) these DEXA-induced increases in nitrotyrosine immunoreactivity, which were comparable with the effects of oxymetholone (Table VIII and Fig. 9).

**Alterations in 4-HNE-immunolabelled muscle fibers.** Significant increases (P<0.01) in 4-HNE (lipid peroxidation marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P<0.01) these DEXA-induced increases in muscle 4-HNE-immunoreactive...
fibers. Oxymetholone also significantly decreased (P<0.01) the number of 4-HNE-positive muscle fiber compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in 4-HNE-immunoreactive fibers, which were comparable with the effects of oxymetholone (Table VIII and Fig. 9).

Alterations in iNOS-immunolabelled muscle fibers. Significant increases (P<0.01) in iNOS (oxidative stress marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P<0.01) these DEXA-induced increases in muscle iNOS-immunoreactive fibers. Oxymetholone also significantly decreased (P<0.01) the number of iNOS-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in iNOS-immunoreactive fibers, which were comparable with the effects of oxymetholone (Table VIII and Fig. 10).
Alterations in myostatin-immunolabelled muscle fibers. Significant increases (P<0.01) in myostatin immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced these DEXA-induced increases in myostatin-immunoreactive fibers. In addition, oxymetholone (50 mg/kg) significantly reduced the number of myostatin-positive muscle fibers as compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in myostatin-immunoreactive fibers, which were comparable with the effects of oxymetholone (50 mg/kg). (A) Deionized distilled water-administered and saline-treated mice (intact vehicle control group). (B) Deionized distilled water-administered and DEXA-treated control mice (DEXA control group). (C) Oxymetholone (50 mg/kg)-administered and DEXA-treated reference mice (oxymetholone group). (D) EAP (400 mg/kg)-administered and DEXA-treated experimental mice (EAP400 group). (E) EAP (200 mg/kg)-administered and DEXA-treated experimental mice (EAP200 group). (F) EAP (100 mg/kg)-administered and DEXA-treated experimental mice (EAP100 group). Scale bars=40 μm. 4-HNE, 4-hydroxynonenal; DEXA, dexamethasone; EAP, extracellular polysaccharides purified from Aureobasidium pullulans SM-2001.

Discussion
Atrophy begins with a decrease in muscle tension, which is associated with reduced protein synthesis and increased protein degradation (68). Four types of proteolytic degradation...
are involved in muscle atrophy: Calpain calcium-dependent signaling, lysosomal proteases (cathepsins), the ubiquitin proteasome pathway and the caspase signaling system (6,68-70). There is a common genetic program involved in muscle proteolysis regardless of its etiology; however, distinct signaling pathways are involved to modulate the system (6,69,71).

Oxidative stress is a well-known and important inducer of muscle atrophy in response to disuse and in catabolic muscle cachexia (71). In addition, apoptosis and loss of muscle fibers are also involved in the early phase of muscle atrophy, regardless of etiology (72,73).

Glucocorticoid-induced catabolic muscle atrophy is characterized by a reduction and degradation in protein content, organelles, cytoplasm, fiber diameter, resistance to fatigue and muscle strength (16,21,23,28,74). Glucocorticoids are immunosuppressants that are clinically used to suppress swelling.

Figure 10. Representative gastrocnemius muscle iNOS and myostatin immunoreactivity. Marked increases in the immunoreactivity of the oxidative stress marker, iNOS, which is a strong negative regulator of muscle growth, and myostatin, were detected in the gastrocnemius muscle bundles from DEXA control mice. However, EAP significantly and dose-dependently reduced these DEXA-induced increases in iNOS- and myostatin-immunoreactive muscle fibers. In addition, oxymetholone (50 mg/kg) significantly decreased the number of iNOS- and myostatin-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in iNOS- and myostatin-immunoreactive fibers, which were comparable with the effects of oxymetholone (50 mg/kg). (A) Deionized distilled water-administered and saline-treated mice (intact vehicle control group). (B) Deionized distilled water-administered and DEXA-treated control mice (DEXA control group). (C) Oxymetholone (50 mg/kg)-administered and DEXA-treated reference mice (oxymetholone group). (D) EAP (400 mg/kg)-administered and DEXA-treated experimental mice (EAP400 group). (E) EAP (200 mg/kg)-administered and DEXA-treated experimental mice (EAP200 group). (F) EAP (100 mg/kg)-administered and DEXA-treated experimental mice (EAP100 group). Scale bars=40 µm. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from Aureobasidium pullulans SM-2001; iNOS, inducible nitric oxide synthase.
and acute inflammation. Millions of people take glucocorticoids as chronic therapy to treat various diseases, including asthma, rheumatoid arthritis, primary or secondary adrenal insufficiency, and organ transplants (23). Common side effects of glucocorticoids include nervousness, insomnia, gastrointestinal upset, immunosuppression, arthralgia, myopathy and edema (75). Glucocorticoids have been in commercial use for >50 years (76); however, their prolonged use is associated with myopathy, particularly with prolonged high doses. Long-term glucocorticoid therapy enhances the risk of muscle weakness and myopathy by 50% (77,78). The characteristic features of myopathy include weakness and muscle atrophy, oxidative stress, mitochondrial dysfunction and insulin resistance. Histological alterations associated with muscle atrophy include loss of myosin filaments in sarcomeres, type II specific atrophy of muscle fibers, preservation of Z-bands and thin filaments, and necrosis (74). Steroid-induced myopathy is not only associated with the use of fluorinated steroids, including triamcinolone, β-methasone and DEXA, but can also be caused by non-fluorinated steroids, such as hydrocortisone and prednisolone (79). In the present study, the potential beneficial skeletal muscle-preserving effects of EAP were examined in a mouse model of DEXA-induced catabolic muscle atrophy.

All of the intact vehicle control mice exhibited normal body weight gain throughout the experimental period, including during the 10 days of acclimation (80,81). The DEXA-induced decreases in body weight detected in the present study were considered to be related to cachexia, due to the potent catabolic effects of DEXA (82,83). Conversely, the increased body weight detected in mice treated with EAP may be associated with the known immunomodulatory effects of EAP (45,84). Generally, good growth patterns are associated with an enhanced immune system (85,86), which is induced by the medical significance of LDH is evident due to its extensive presence in body tissues, including heart muscle and blood cells. CK is an enzyme expressed by various tissues and cell types, which is involved in the conversion of creatine and the consumption of adenosine. Since LDH and CK are released during tissue damage, they are considered markers of common disease and injuries, particularly muscle damage. Plasma activities of CK and LDH have been used commonly as markers of muscle tissue damage (26,98,99). They are also markedly elevated in animals with disused muscle atrophy (100). In a DEXA-induced animal model of catabolic muscle atrophy, marked elevations in serum CK levels were noted; however, serum LDH levels were generally decreased due to reduced physiological activity and skeletal muscle fiber concentration (24,26,101). Significantly elevated serum CK levels, indicating decreases in serum LDH levels and muscle damage, thus signifying reduced muscle activity, were demonstrated in the DEXA control mice in the present study. However, significant and dose-dependent decreases in serum CK and increases in serum LDH levels were detected in 100, 200, and 400 mg/kg EAP-treated mice; these effects were comparable with those of 50 mg/kg oxymetholone. In particular, 400 mg/kg EAP exhibited favorable and potent muscle-preserving effects.

Lipid peroxidation can harm surrounding tissues due to the release of various toxic substances (102), and oxidative stress is a significant inducer of muscle atrophy (71). Inhibition of increased lipid peroxidation protects muscles against atrophic alterations (57,103,104). Nitrotyrosine, which is a product of tyrosine nitration that has been detected in numerous pathological disorders, is known as a marker of iNOS-dependent nitrate stress (105-107). In addition, it has been demonstrated to damage antioxidant defense systems in muscle tissues; this was associated with glucocorticoid-induced catabolic muscle atrophic alterations (26,71,108). In the present study, EAP dose-dependently protected the gastrocnemius muscle against DEXA-triggered oxidative stress, reduced DEXA-induced increases in lipid peroxidation and ROS formation, increased DEXA-induced decreases in CAT and SOD activities and GSH contents, and reduced DEXA-induced increases in nitrotyrosine and 4-HNE-immunolabelled muscle fibers. Oxymetholone also exerted strong antioxidative effects against DEXA-induced depletion of antioxidant defense systems, consistent with other studies on anabolic steroids (109,110) and 1.7% of creatine is metabolized per day via non-enzymatic hydrolytic cyclization (93,94). Creatine rapidly diffuses from the muscle into the plasma and is transferred to the urine, with no uptake into muscles (90,95). Therefore, plasma creatine levels can be used as a serum biochemical indicator for skeletal muscle damage, activity or muscle quantity (26,96,97). In the present study, marked increases in serum creatine levels were verified alongside other DEXA-associated catabolic muscle atrophic alterations; this finding was similar to those of previous studies (16,26). Oral administration of 100, 200 and 400 mg/kg EAP significantly and dose-dependently limited the DEXA-induced increases in serum creatine levels. Particularly, 400 mg/kg EAP exhibited favorable inhibitory effects on serum creatine level elevations; these effects were comparable with those of 50 mg/kg oxymetholone, thus indicating that EAP exerts positive muscle-preserving effects against glucocorticoid-induced atrophy.
previous results in glucocorticoid-induced catabolic muscle atrophic mice (26).

Apoptosis and muscle fiber damage are associated with the early phase of muscle atrophy regardless of etiology (72,73), and caspase-3 and PARP serve key roles in apoptosis (111,112). Increases in the number of caspase-3 and PARP-immunoreactive muscle fibers in muscle bundles indicate apoptosis and related damage (26,113,114). Furthermore, treatment with glucocorticoids has been reported to induce marked apoptosis in muscles (23,26). Therefore, EAP-induced dose-dependent inhibition of caspase-3 and PARP immunoreactivity in DEXA-treated gastrocnemius muscle bundles may provide direct evidence that EAP can preserve muscle mass through inhibitory effects against DEXA-induced muscle fiber apoptosis.

Muscle structure and mass are evaluated by the equilibrium between protein synthesis and degradation (70). Protein degradation, which is responsible for muscle wasting, is triggered by ATP-ubiquitin-dependent proteolysis (9). A previous study reported that the muscle-specific E3 ubiquitin ligases, including MuRF1 and atrogin-1, are important for muscle atrophy (6). In addition, it has been revealed that the expression levels of MuRF1 and atrogin-1 are increased in atrophic skeletal muscles, and mice deficient in MuRF1 or atrogin-1 are resistant to muscle atrophy (5,115,116). In addition, marked increases in the mRNA expression levels of MuRF1 and atrogin-1 have been observed in glucocorticoid-induced catabolic atrophic muscles (16,26,28). In the present study, marked elevations in the mRNA expression levels of MuRF1 and atrogin-1 in gastrocnemius muscles were detected in the DEXA control group compared with in the intact vehicle control group; however, these elevations were dose-dependently inhibited following treatment with EAP, providing direct evidence to suggest that EAP exerts muscle-protective effects apparently mediated through downregulation of atrogin-1 and MuRF1. In particular, 400 mg/kg EAP exhibited favorable inhibitory effects on muscle atrogin-1 and MuRF1 mRNA expression; these effects were comparable with those of oxymetholone.

Protein synthesis is activated by the insulin-like growth factor 1 (IGF-1)/PI3K/Akt pathway (6,70). PI3K, which is initiated by IGF or insulin, in turn activates the serine/threonine kinase Akt (69). Marked downregulation of PI3K and Akt1 mRNA expression were detected in DEXA-treated mice with catabolic muscle atrophic alterations; this finding was consistent with the results of a previous study (26). Conversely, EAP dose-dependently upregulated the mRNA expression levels of Akt1 and PI3K compared with in the DEXA control group, which indicated that EAP may resist glucocorticoid-induced muscle atrophy and activate muscle protein synthesis; these effects were comparable with those of oxymetholone. Notably, 400 mg/kg EAP exhibited favorable upregulating effects on Akt1 and PI3K mRNA expression, comparable with those of oxymetholone.

Adenosine modulates numerous physiological functions in various tissues, including skeletal muscle and the cardiovascular system (117-119). Adenosine is considered to be involved in the synergistic effects of contraction- and insulin-stimulated glucose uptake in skeletal muscle, and in the regulation of blood flow to skeletal muscle (120,121). Specific adenosine receptors are associated with facilitation of the physiological effects of adenosine (122). TRPV4 is a member of the TRP channel superfamily (123,124), which serves an osmosensory or mechanosensory role in numerous musculoskeletal tissues, and prevents muscle atrophy and bone loss (124,125). Subcutaneous treatment with DEXA significantly decreased the mRNA expression levels of TRPV4 and A1R in gastrocnemius muscle, which may be associated with catabolic muscle atrophy-related proteolysis; these findings were similar to those of a previous study (26). EAP dose-dependently upregulated A1R and TRPV4 mRNA expression compared with in the DEXA control group, providing direct evidence that 400 mg/kg EAP can increase muscle growth and resist DEXA-induced catabolic muscle atrophy; these effects were comparable with those of 50 mg/kg oxymetholone.

Myostatin is a secreted growth differentiation factor that inhibits growth and muscle differentiation in myogenesis. It is a powerful negative controller of muscle growth (9,16). The sirtuin protein family (SIRT1-7) possesses ADP ribosyltransferase activity and/or NAD^+-dependent deacetylase activity (126). SIRT1 controls numerous biological processes, including differentiation, cell proliferation, metabolism and apoptosis (127). In addition, it regulates transcription of peroxisome proliferator-activated receptor-γ co-activator 1α in skeletal muscle (128) and inhibits muscle regeneration, which causes cachexia (129). In catabolic muscle atrophy, the mRNA expression levels of SIRT1 and myostatin have been detected alongside decreases in muscle mass (16,25,26,130); similar findings were induced with DEXA treatment in the present study. However, elevations in the expression levels of SIRT1, a representative inhibitor of muscle regeneration, and myostatin, a strong negative regulator of muscle growth, were dose-dependently inhibited by treatment with EAP. In addition, EAP dose-dependently inhibited increases in myostatin-immunoreactive fibers, as determined by immunohistochemical analysis, providing evidence of muscle-shielding effects via downregulation of SIRT1 and myostatin. Notably, 400 mg/kg EAP exhibited favorable inhibitory effects on muscle myostatin and SIRT1 mRNA expression, and myostatin immunoreactivity in muscle fibers; these effects were comparable with those of 50 mg/kg oxymetholone.

Glucocorticoid-induced catabolic muscle atrophic alterations have been reported to induce marked histopathological alterations, including microvacuolation, diminished muscle fiber diameter, fibrosis and collagen deposition, as well protein degradation (15,21,26); these alterations were observed in the present study. However, in the present study, muscle atrophy-associated alterations were reduced by treatment with oxymetholone or EAP. These findings suggested that oxymetholone or EAP may protect muscles against DEXA-induced catabolic atrophy. EAP exhibited favorable inhibitory effects on histopathological muscle fibrosis and atrophic alterations, which were compared with the effects of oxymetholone.

In conclusion, EAP exerted favorable ameliorating effects on DEXA-induced catabolic muscle atrophy via anti-inflammatory and antioxidant effects, which were mediated by modulation of the expression of genes associated with muscle protein synthesis (Akt1, PI3K, A1R and TRPV4) and degradation (atrogin-1, MuRF1, myostatin and SIRT1). Therefore, EAP may be helpful in improving various muscle atrophy conditions with...
various etiologies. Notably, 400 mg/kg EAP exhibited favorable muscle-protective effects against DEXA-induced catabolic muscle atrophy, which were comparable with the effects of 50 mg/kg oxymetholone.

Acknowledgements

The present study was financially supported by the Ministry of Trade, Industry, and Energy, Korea, under the ‘Regional Specialized Industry Development Program’ (grant no. R0005069). Development of functional food products for improving the locomotive syndrome using black yeast [β-glucan] supervised by the Korea Institute for Advancement of Technology.

References

1. Brooks SV and Faulkner JA: Skeletal muscle weakness in old age: Underlying mechanisms. Med Sci Sports Exerc 26: 432-439, 1994.
2. Frontera WR, Hughes VA, Fielding RA, Fiatarone MA, Evans WJ: Effects of weight training on muscle mass, strength, and endurance in aging men. J Appl Physiol 88: 1211-1216, 2000.
3. Metter EJ, Talbot LA, Schrager M and Convit R: Skeletal muscle strength as a predictor of all-cause mortality in healthy men. J Gerontol A Biol Sci Med Sci 57: B359-B365, 2002.
4. Glass DJ: Molecular mechanisms modulating muscle mass. Trends Mol Med 9: 344-350, 2003.
5. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, et al: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001.
6. Glayda D: Muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37: 1974‑1984, 2005.
7. Ramírez C, Russo TL, Sandoval DC, Dentillo AA, Couto MA, Durigan JL and Salvini TF: Joint inflammation alters gene and protein expression and leads to atrophy in the tibialis anterior muscle. Am J Phys Med Rehabil 90: 930‑939, 2011.
8. Hofer T, Marzetti E, Xu J, Seo AY, Gulec S, Knutson MD, et al: Effects of spaceflight on murine skeletal muscle expression. J Appl Physiol 1985 106: 582‑595, 2009.
9. Kim JW, Ku SK, Han MH, Kim KY, Kim SG, Kim GY, Hwang HJ, Kim BW, Kim CM and Choi YH: The administration of Fructus Schisandraceae attenuates dexamethasone-induced muscle atrophy in mice. Int J Mol Sci 36: 29‑42, 2015a.
10. Benveniste O, Jacobson L, Farrugia ME, Clover L and Vincent A: MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. J Neuroimmunol 170: 41‑48, 2005.
11. Jones A, Hwang DJ, Narayanan R, Miller DD and Dalton JT: Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology 151: 3706‑3719, 2010.
12. Yang Z, Nakagawa K, Sarkar A, Maruyama J, Iwasa H, Bao Y, Ishigami-Yuasa M, Ito S, Kagechika H, Hata S, et al: Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model. Mol Cell Biol 34: 1607‑1621, 2014.
13. Ringgold HJ, Batres E, Halpren O and Necocoecha E: Steroids. CV, V 2‑Methyl and 2‑hydroxymethylene‑androstane derivatives. J Am Chem Soc 81: 427‑432, 1959.
14. Lenardon HD: Effects of various 17‑alpha‑alkyl substitutions and structural modifications of steroids on sulfobromophthalein (BSP) retention in rabbits. Steroids 7: 157‑176, 1966.
15. Dorfman RI and Kinel FA: Relative potency of steroids in an anabolic‑androgenic assay using the castrated rat. Endocrinology 72: 250‑266, 1965.
16. Pavlatos AM, Fultz O, Monberg MJ and Vootkur A: Review of oxymetholone: A 17alpha-alkylated anabolic-androgenic steroid. Clin Ther 23: 789‑801, discussion 771, 2001.
17. Isaacs J, Loveland K, Malti S, Adams S and Wodicka R: The use of anabolic steroids as a strategy in reversing denervation atrophy after delayed nerve repair. Hand (NY) 6: 142‑148, 2011.
18. Kim JW, Ku SK, Kim KY, Kim SG, Han MH, Kim GY, Hwang HJ, Kim BW, Kim CM and Choi YH: Schisandraceae Fructus supplementation ameliorates sciatric neuromyopathy-induced muscle atrophy in mice. Oxf Med Cell Longev 2015: 872428, 2015.
19. Young GP, Bhattachai PS, Sullivan JR, Wall AJ, Fone DJ and Hurley TH: Fatal hepatic coma complicating oxymetholone therapy in multiple myeloma. Aust N Z J Med 7: 47‑51, 1977.
20. Wood P and Yin JA: Oxymetholone hepatotoxicity enhanced by concomitant use of cyclosporin A in a bone marrow transplant patient. Clin Lab Haematol 16: 201‑204, 1994.
21. Walker ID, Davidson JS, Young P and Conkie JA: Plasma fibrinolytic activity following oral anabolic steroid therapy. Thromb Haematol 34: 231‑234, 1990.
22. Tzitzikas AO: Polysaccharide immunomodulators as therapeutic agents: Structural aspects and biologic function. Clin Microbiol Rev 13: 523‑533, 2000.
87. Hengge UR, Baumann M, Maleba R, Brockmeyer NH and Goos M: Oxyymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV)-1 infection. Br J Nutr 75: 129‑138, 1996.
88. Hengge UR, Stocks K, Faulkner S, Wiehler H, Lorenz C, Jentzen W, Hengge D and Ringham G: Oxyymetholone for the treatment of HIV-wasting: A double-blind, randomized, placebo‑controlled phase III trial in eugonadal men and women. HIV Clin Trials 4: 150‑163, 2003.
89. Hengge UR, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, Jentzen W, Hengge D, Goos M, Dudley RE, et al: Double-blind, randomized, placebo‑controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS 17: 699‑710, 2003.
90. Wys M and Kaddurah‑Daouk R: Creatine and creatinine. Physiol Rev 80: 1107‑1213, 2000.
91. Hunter A (ed): The biological distribution of creatine and creatine metabolism. Physiol Rev 80: 1107‑1213, 2000.
92. Balsom PD, Sederlund K and Ekblom B: Creatine in humans with special reference to creatine supplementation. Sports Med 18: 268‑280, 1994.
93. Fitch CD, Lucy DD, Bornhofen JH and Klompp GV: Creatine metabolism in skeletal muscle. II. Creatine kinetics in man. Neurology 18: 32‑42, 1968.
94. Bloch K and Schoenheimer R: Studies in protein metabolism. XI. The distribution of creatine and creatine phosphate in tissues of normal and ischemic muscles with isotopic nitrogen. J Biol Chem 131: 111‑119, 1939.
95. Heymsfield SB, Artega C, McManus C, Smith J and Moffitt S: Measurement of muscle mass in humans: Validity of the 24‑hour urinary creatinine method. Am J Clin Nutr 37: 478‑494, 1983.
96. Sala A, Tarnopolsky M, Webber C, Norman G and Barr R: Serum creatine: A surrogate measurement of lean body mass in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 49: 16‑20, 2007.
97. Stimpson SA, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, Jentzen W, Hengge D, Goos M, Dudley RE, et al: Double-blind, randomized, placebo‑controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS 17: 699‑710, 2003.
98. Wys M and Kaddurah‑Daouk R: Creatine and creatinine. Physiol Rev 80: 1107‑1213, 2000.
99. Hunter A (ed): The biological distribution of creatine and creatine metabolism. Physiol Rev 80: 1107‑1213, 2000.
100. Balsom PD, Sederlund K and Ekblom B: Creatine in humans with special reference to creatine supplementation. Sports Med 18: 268‑280, 1994.
101. Fitch CD, Lucy DD, Bornhofen JH and Klompp GV: Creatine metabolism in skeletal muscle. II. Creatine kinetics in man. Neurology 18: 32‑42, 1968.
102. Bloch K and Schoenheimer R: Studies in protein metabolism. XI. The distribution of creatine and creatine phosphate in tissues of normal and ischemic muscles with isotopic nitrogen. J Biol Chem 131: 111‑119, 1939.
103. Heymsfield SB, Artega C, McManus C, Smith J and Moffitt S: Measurement of muscle mass in humans: Validity of the 24‑hour urinary creatinine method. Am J Clin Nutr 37: 478‑494, 1983.
104. Süleyman H, Cadirci E, Albayrak A, Polat B, Halici Z, Fitch CD, Lucy DD, Bornhofen JH and Dalrymple GV: Effects of EAP on Dexamethasone‑Induced Muscular Atrophy.